Pain relief in oral mucositis
OncoZenge develops better products for cancer supportive care. Preparations for Phase 3 is ongoing for our lead asset BupiZenge® following superior Phase 2 data vs Standard of care in patients with oral mucositis.
5 million people worldwide suffer from oral mucositis after cancer therapy. Oral mucositis is the most debilitating side effect of radiation therapy and chemotherapy. After radiotherapy in the head and neck region, 90% of patients develop OM and of the patients treated with chemotherapy, about 30% are affected. OM causes severe pain, interruption of cancer treatments and increased healthcare costs.
BioStock article on OncoZenge
Interview with CEO Pirkko Tamsen at Biostock (in Swedish)
link to interview
2021-01-04 OncoZenge´s listing on Nasdaq First North Growth Market
link to video
2021-01-04 Interview with CEO Pirkko Tamsen
link to video
OM causes severe pain
Oral mucositis has a significant impact on the quality of life of cancer patients. It may cause severe pain, difficulties in eating and drinking as well as in swallowing and communicating. OM leads to:
- 62% of patients need to be hospitalized*
- 70% of patients need tube feeding*
- 35% of patients must reduce the dose or discontinue their cancer treatment*
In clinical studies, BupiZenge® has been shown to significantly reduce pain in the mouth and throat.
*Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M. Perspectives on cancer therapy-induced mucosal injury. Cancer. 2004;100(9 Suppl):1995-2025
THE SUBSCRIPTION PERIOD FOR ONCOZENGE´S RIGHTS ISSUE BEGINS TODAY
THE LAST DAY FOR TRADING IN THE RIGHT TO RECEIVE SUBSCRIPTION RIGHTS IS TODAY, FEBRUARY 15, 2021
CORRECTION REGARDING ISIN CODE FOR THE SHARE IN THE PROSPECTUS
ONCOZENGE HAS OBTAINED A CONDITIONAL APPROVAL FOR LISTING ON NASDAQ FIRST NORTH GROWTH MARKET AND PUBLISHES PROSPECTUS
ANNOUNCEMENT OF TERMS FOR THE FULLY GUARANTEED RIGHTS ISSUE IN ONCOZENGE, TIMETABLE FOR THE LISTING AND RECORD DATE FOR LEX ASEA
OncoZenge is a Swedish pharmaceutical company founded in 2020 as a spin-out from Moberg Pharma in collaboration with leading clinicians from Hvidovre Hospital in Denmark.
The original invention was made in 2011 by Professor Ove Andersen and his team who developed a novel concept to provide better pain relief for patients with OM. Since then clinical studies in Phase 1 and Phase 2 have demonstrated the efficacy and safety of BupiZenge®.
Subscribe to press releases & financial reports
Add your e-mail adress to get the latest news and reports
BupiZenge® can radically improve quality of life for patients with severe oral pain, originating for example from radiation therapy or chemotherapy of cancer.More about our main project BupiZenge® here